Intech Investment Management LLC Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Intech Investment Management LLC boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 64.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 92,300 shares of the medical equipment provider’s stock after purchasing an additional 36,104 shares during the quarter. Intech Investment Management LLC’s holdings in Hologic were worth $6,654,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. General Partner Inc. purchased a new stake in shares of Hologic during the fourth quarter worth about $26,000. Venturi Wealth Management LLC grew its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.3 %

Shares of HOLX opened at $61.98 on Wednesday. The company’s fifty day simple moving average is $66.72 and its 200-day simple moving average is $74.37. The company has a market cap of $13.91 billion, a P/E ratio of 19.55, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Finally, Royal Bank of Canada lowered their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.